Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
Suspected stent thrombosis or ACS needs emergency assessment; major or intracranial bleeding on antiplatelets requires immediate resuscitation, haemostasis and senior cardiology/haematology input.
Synopsis
Select and monitor antiplatelet treatment for UK cardiovascular indications while recognising bleeding and thrombotic emergencies.
Antiplatelets prevent platelet-rich arterial thrombosis; they are not interchangeable with anticoagulants.
Give aspirin as soon as possible in suspected ACS unless there is a true contraindication.
Dual antiplatelet therapy means aspirin plus one P2Y12 inhibitor; indication and duration depend on ACS, PCI and bleeding risk.
Key red flags
ACS or stent thrombosis
New ischaemic chest pain, dynamic ECG change, troponin rise or abrupt symptoms after PCI require emergency ACS care.
Investigation priorities
01
12-lead ECG and serial troponinFirst step
Assess suspected ACS or stent thrombosis.
Management branches
FirstSuspected acute coronary syndrome
Ischaemic chest pain or equivalent with possible ACS.
Perform immediate ABC assessment, 12-lead ECG and activate the national ACS/reperfusion pathway when indicated.
Give aspirin 300 mg orally as soon as possible unless genuinely contraindicated.
NextLong-term secondary prevention
Stable after MI, PCI, ischaemic stroke/TIA or symptomatic peripheral arterial disease.
Clopidogrel75 mg orally once daily. In non-ST-elevation ACS, use a 300 mg or 600 mg loading dose; a 600 mg load may be considered before PCI in adults under 75. STEMI and fibrinolysis regimens are timing- and age-specific.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.